indirubin has been researched along with Acute Myelogenous Leukemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SJ; Choi, SU; Han, SY; Kim, YC; Lee, SD; Moon, MJ | 1 |
| Han, SY; Jeong, P; Kim, MJ; Kim, W; Kim, YC; Lee, HJ; Lee, JH; Oh, SJ; Park, HW; Shin, JE | 1 |
| Baudet, A; Cammenga, J; Davidsson, J; Ek, F; Juliusson, G; Magnusson, M; Olsson, R; Soneji, S | 1 |
3 other study(ies) available for indirubin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Leukemia, Myeloid, Acute | 2010 |
Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.
Topics: Acetamides; Amides; Animals; Antineoplastic Agents; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors | 2022 |
Small molecule screen identifies differentiation-promoting compounds targeting genetically diverse acute myeloid leukaemia.
Topics: Cell Differentiation; Cell Line, Tumor; Coculture Techniques; Early Detection of Cancer; Genetic Variation; Humans; Indoles; Leukemia, Myeloid, Acute; Small Molecule Libraries | 2016 |